French Trial Tragedy May Spark Change In EU Phase I Risk Assessments
This article was originally published in SRA
Drug regulators in the EU are looking closely at the way that Phase I studies are planned and designed amid calls for better protection for volunteers in the wake of the French BIA 10-2474 trial tragedy. Among topics likely to be under consideration are a more consistent approach to determining the potential risk of novel compounds, and greater use of sequential dosing in first-in-human clinical trials.
Register for our free email digests: